Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression (Q43501092)

24 November 2017

title

Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression (English)

1 reference

24 November 2017

5

1 reference

24 November 2017

Simon L Goodman

3

0 references

author name string

Christine Böger

series ordinal

1

1 reference

24 November 2017

Holger Kalthoff

series ordinal

2

1 reference

24 November 2017

Hans-Michael Behrens

series ordinal

4

1 reference

24 November 2017

publication date

26 November 2013

1 reference

24 November 2017

1 reference

24 November 2017

volume

464

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

69-78

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

24 November 2017

1 reference

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Involvement of integrin alpha V gene expression in human melanoma tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Targeting integrins in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Integrin ligands at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

The role of alpha v-integrins in tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Ligand binding to integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Demystified...tissue microarray technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

The spatial distribution of LGR5+ cells correlates with gastric cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Integrins as target: first phase III trial launches, but questions remain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Differential osteopontin expression in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Clinical impact of ki-67 labeling index in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Osteopontin is a marker for cancer aggressiveness and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Discovering the false discovery rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1506-1

Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs

21 January 2018

1 reference

12 December 2020

Osteopontin: possible role in prostate cancer progression

1 reference

12 December 2020

Co-expression of osteopontin and CD44v9 in gastric cancer

1 reference

12 December 2020

Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.

1 reference

12 December 2020

Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro

1 reference

12 December 2020

An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice.

1 reference

12 December 2020

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

1 reference

12 December 2020

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

1 reference

12 December 2020

Personalized targeted therapy for lung cancer

1 reference

12 December 2020

Osteopontin Expression and Prognostic Significance in Non-Small Cell Lung Cancer

1 reference

12 December 2020

Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma.

1 reference

12 December 2020

Loss of alpha-v integrin expression and recurrence in node-negative lung carcinoma

1 reference

12 December 2020

Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung

1 reference

12 December 2020

1 reference

12 December 2020

Osteopontin expression in lung cancer

1 reference

12 December 2020

In vivo therapy of malignant melanoma by means of antagonists of alphav integrins

1 reference

12 December 2020

[TNM classification of malignant tumors 2010: General aspects and amendments in the general section]

1 reference

12 December 2020

Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas

1 reference

12 December 2020

EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: comparison of 3 commercially available EGFR-antibodies

1 reference

12 December 2020

10.1007/S00428-013-1506-1

Identifiers

DOI

1 reference

Dimensions Publication ID

24 November 2017

1010946187

0 references

1 reference